

Table 2.5. Nested case–control study of Epstein-Barr virus infection markers and Kaposi sarcoma and non-Hodgkin lymphoma

Reference, study location and period	Characteristics of cases	Characteristics of controls	Detection method	Exposure categories	Relative risk (95% CI)	Adjusted potential confounders	Comments
Newton <i>et al</i> (2006)	189 HIV-infected Kaposi's sarcoma cases 67 HIV-infected non-Hodgkin's lymphoma	HIV-1 infected control matched (1:1) with each case matched on trial, age, sex, HIV transmission group, treatment group, ethnicity, length of time from entry to the trial	IgG antibodies to EBV VCA	Doubling of Anti-EBV VCA (IgG) antibody titer	Kaposi's sarcoma 1.0 (0.8–1.2) Non-Hodgkin's lymphoma 1.5 (0.9–2.3)	CD4 counts at the time of sample detection	Both cases and control were HIV-infected Reference category is not uninfected people. RR refers to doubling of anti-EBV VCA (IgG) antibody titer.